Research programme: universal chimeric antigen receptor T-cell therapeutics - Base Therapeutics
Latest Information Update: 06 Mar 2024
At a glance
- Originator Base Therapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 03 Jan 2024 Early research in Unspecified in China (Parenteral) prior to January 2024 (Base Therapeutics pipeline, January 2024)